Machine learning-enabled maternal risk assessment for women with pre-eclampsia (the PIERS-ML model): a modelling study
Tünde Montgomery-Csobán,Kimberley Kavanagh,Paul Murray,Chris Robertson,Sarah J E Barry,U Vivian Ukah,Beth A Payne,Kypros H Nicolaides,Argyro Syngelaki,Olivia Ionescu,Ranjit Akolekar,Jennifer A Hutcheon,Laura A Magee,Peter von Dadelszen,PIERS Consortium,Mark A. Brown,Gregory K. Davis,Claire Parker,Barry N. Walters,Nelson Sass,J. Mark Ansermino,Vivien Cao,Geoffrey W. Cundiff,Emma C.M. von Dadelszen,M. Joanne Douglas,Guy A. Dumont,Dustin T. Dunsmuir,Jennifer A. Hutcheon,K.S. Joseph,Sayrin Lalji,Tang Lee,Jing Li,Kenneth I. Lim,Sarka Lisonkova,Paula Lott,Jennifer M. Menzies,Alexandra L. Millman,Lynne Palmer,Beth A. Payne,Ziguang Qu,James A. Russell,Diane Sawchuck,Dorothy Shaw,D. Keith Still,U. Vivian Ukah,Brenda Wagner,Keith R. Walley,Dany Hugo,The late Andrée Gruslin,George Tawagi,Graeme N. Smith,Anne-Marie Côté,Jean-Marie Moutquin,Annie B. Ouellet,Shoo K. Lee,Tao Duan,Jian Zhou,The late Farizah Haniff,Swati Mahajan,Amanda Noovao,Hanna Karjalainend,Alja Kortelainen,Hannele Laivuori,J. Wessel Ganzevoort,Henk Groen,Phillipa M. Kyle,M. Peter Moore,Barbra Pullar,Zulfiqar A. Bhutta,Rahat N. Qureshi,Rozina Sikandar,The late Shereen Z. Bhutta,Garth Cloete,David R. Hall,The late Erika van Papendorp,D. Wilhelm Steyn,Christine Biryabarema,Florence Mirembe,Annettee Nakimuli,John Allotey,Shakila Thangaratinam,Kypros H. Nicolaides,Olivia Ionescu,Argyro Syngelaki,Michael de Swiet,Laura A. Magee,Peter von Dadelszen,Ranjit Akolekar,James J. Walker,Stephen C. Robson,Fiona Broughton-Pipkin,Pamela Loughna,Manu Vatish,Christopher W.G. Redman,Sarah J.E. Barry,Kimberley Kavanagh,Tunde Montgomery-Csobán,Paul Murray,Chris Robertson,Eleni Z. Tsigas,Douglas A. Woelkers,Marshall D. Lindheimer,William A. Grobman,Baha M. Sibai,Mario Merialdi,Mariana Widmer
DOI: https://doi.org/10.1016/s2589-7500(23)00267-4
IF: 36.615
2024-04-01
The Lancet Digital Health
Abstract:BACKGROUND: Affecting 2-4% of pregnancies, pre-eclampsia is a leading cause of maternal death and morbidity worldwide. Using routinely available data, we aimed to develop and validate a novel machine learning-based and clinical setting-responsive time-of-disease model to rule out and rule in adverse maternal outcomes in women presenting with pre-eclampsia.METHODS: We used health system, demographic, and clinical data from the day of first assessment with pre-eclampsia to predict a Delphi-derived composite outcome of maternal mortality or severe morbidity within 2 days. Machine learning methods, multiple imputation, and ten-fold cross-validation were used to fit models on a development dataset (75% of combined published data of 8843 patients from 11 low-income, middle-income, and high-income countries). Validation was undertaken on the unseen 25%, and an additional external validation was performed in 2901 inpatient women admitted with pre-eclampsia to two hospitals in south-east England. Predictive risk accuracy was determined by area-under-the-receiver-operator characteristic (AUROC), and risk categories were data-driven and defined by negative (-LR) and positive (+LR) likelihood ratios.FINDINGS: Of 8843 participants, 590 (6·7%) developed the composite adverse maternal outcome within 2 days, 813 (9·2%) within 7 days, and 1083 (12·2%) at any time. An 18-variable random forest-based prediction model, PIERS-ML, was accurate (AUROC 0·80 [95% CI 0·76-0·84] vs the currently used logistic regression model, fullPIERS: AUROC 0·68 [0·63-0·74]) and categorised women into very low risk (-LR <0·1; eight [0·7%] of 1103 women), low risk (-LR 0·1 to 0·2; 321 [29·1%] women), moderate risk (-LR >0·2 and +LR <5·0; 676 [61·3%] women), high risk (+LR 5·0 to 10·0, 87 [7·9%] women), and very high risk (+LR >10·0; 11 [1·0%] women). Adverse maternal event rates were 0% for very low risk, 2% for low risk, 5% for moderate risk, 26% for high risk, and 91% for very high risk within 48 h. The 2901 women in the external validation dataset were accurately classified as being at very low risk (0% with outcomes), low risk (1%), moderate risk (4%), high risk (33%), or very high risk (67%).INTERPRETATION: The PIERS-ML model improves identification of women with pre-eclampsia who are at lowest and greatest risk of severe adverse maternal outcomes within 2 days of assessment, and can support provision of accurate guidance to women, their families, and their maternity care providers.FUNDING: University of Strathclyde Diversity in Data Linkage Centre for Doctoral Training, the Fetal Medicine Foundation, The Canadian Institutes of Health Research, and the Bill & Melinda Gates Foundation.
medicine, general & internal,medical informatics